Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking

Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use

Extracellular vesicles (EVs) derived from stem and progenitor cells may have therapeutic effects comparable to their parental cells and are considered promising agents for the treatment of a variety of diseases. To this end, strategies must be designed to successfully translate EV research and to develop safe and efficacious therapies, whilst taking into account the applicable regulations. Here...

Natural Therapeutics Targeting Survivin

Volume 1 • Issue 6 • 1000e121 Biochem Anal Biochem ISSN:2161-1009 Biochem, an open access journal An interesting study analysing the effect of curcumin on hepatocellular carcinoma cells revealed the decreased efficacy of curcumin treatment on cells when survivin is suppressed. Using siRNA methods, survivin was suppressed in HCC cells and curcumin was tested for its anticancer effects. Interesti...

LRRK2 and vesicle trafficking.

Mutations in LRRK2 (leucine-rich repeat kinase 2) (also known as PARK8 or dardarin) are responsible for the autosomal-dominant form of PD (Parkinson's disease). LRRK2 mutations were found in approximately 3-5% of familial and 1-3% of sporadic PD cases with the highest prevalence (up to 40%) in North Africans and Ashkenazi Jews. To date, mutations in LRRK2 are a major genetic risk factor for fam...

Exercise-Regulated Vesicle Trafficking

Nanoemulsion Based Targeting in Cancer Therapeutics

A major hurdle in cancer diagnosis and therapy is the targeted and efficacious delivery of agents to the tumor site, while avoiding adverse damage resulting from systemic administration. While systemic drug delivery already hinges largely on physicochemical properties of the drug, such as size, diffusivity, and plasma protein binding affinity, tumors possess a dense, heterogeneous vasculature a...